“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in -
Last close As at 09/06/2023
-6.60
— 0.00 (0.00%)
Market capitalisation
AUD15m
Forecast net debt (A$m)
N/A
Forecast gearing ratio (%)
N/A
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | 0.0 | (5.7) | (52.7) |
| Relative | 4.4 | (4.0) | (49.9) |
| 52 week high/low | A$19.5/A$6.5 |
Edison Investment Research is terminating coverage on Medlab Clinical (MDC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
| Y/E Jun | Revenue (A$m) | EBITDA (A$m) | PBT (A$m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 8.1 | (11.4) | (12.4) | (627.0) | N/A | N/A |
| 2022A | 6.0 | (7.4) | (8.4) | (314.0) | N/A | N/A |
| 2023E | N/A | N/A | N/A | N/A | N/A | N/A |
| 2024E | N/A | N/A | N/A | N/A | N/A | N/A |
Managing Director - Head of Content, Healthcare
Get access to the very latest content matched to your personal investment style.
